300966 共同药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-3.615-2.9422.4464.63411.677
总资产报酬率 ROA (%)-1.149-1.0541.0192.4517.772
投入资产回报率 ROIC (%)-1.518-1.3601.2392.8898.997

边际利润分析
销售毛利率 (%)18.49219.67322.09122.86226.386
营业利润率 (%)-11.524-7.9063.4486.43510.613
息税前利润/营业总收入 (%)-4.281-4.2845.2068.05115.467
净利润/营业总收入 (%)-8.225-5.8993.7596.53613.212

收益指标分析
经营活动净收益/利润总额(%)93.31881.610126.53799.92072.662
价值变动净收益/利润总额(%)0.6690.7671.289-0.474-1.219
营业外收支净额/利润总额(%)2.2686.837-2.164-1.01227.178

偿债能力分析
流动比率 (X)1.0220.9531.2672.1072.576
速动比率 (X)0.4190.4770.6901.3561.462
资产负债率 (%)66.46963.63158.17552.58531.606
带息债务/全部投入资本 (%)53.36248.60847.01942.80916.758
股东权益/带息债务 (%)75.04190.535103.431123.588467.952
股东权益/负债合计 (%)45.89152.00166.90885.291210.813
利息保障倍数 (X)-0.570-1.0192.8444.79017.330

营运能力分析
应收账款周转天数 (天)105.979133.799121.732106.324119.245
存货周转天数 (天)307.514326.128338.014310.224236.696